Is Biomarin Pharmaceutical Stock a Good Investment?
Biomarin Pharmaceutical Investment Advice | BMRN |
- Examine Biomarin Pharmaceutical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biomarin Pharmaceutical's leadership team and their track record. Good management can help Biomarin Pharmaceutical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Biomarin Pharmaceutical's business and its evolving consumer preferences.
- Compare Biomarin Pharmaceutical's performance and market position to its competitors. Analyze how Biomarin Pharmaceutical is positioned in terms of product offerings, innovation, and market share.
- Check if Biomarin Pharmaceutical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biomarin Pharmaceutical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biomarin Pharmaceutical stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biomarin Pharmaceutical is a good investment.
Sell | Buy |
Sell
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Biomarin Pharmaceutical Stock
Researching Biomarin Pharmaceutical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Biomarin Pharmaceutical was currently reported as 29.66. The company has Price/Earnings To Growth (PEG) ratio of 0.49. Biomarin Pharmaceutical had not issued any dividends in recent years.
To determine if Biomarin Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biomarin Pharmaceutical's research are outlined below:
| Biomarin Pharmaceutical is unlikely to experience financial distress in the next 2 years | |
| Biomarin Pharmaceutical has a very strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Q4 Rundown Moderna Vs Other Therapeutics Stocks |
Biomarin Pharmaceutical Quarterly Cash And Short Term Investments |
|
Biomarin Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biomarin Pharmaceutical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomarin Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Biomarin Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Biomarin Pharmaceutical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2008-08-05 | 2008-06-30 | 0.03 | 0.04 | 0.01 | 33 | ||
2008-02-26 | 2007-12-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2009-07-30 | 2009-06-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2008-10-28 | 2008-09-30 | 0.03 | 0.01 | -0.02 | 66 | ||
2007-08-07 | 2007-06-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2007-02-20 | 2006-12-31 | -0.13 | -0.11 | 0.02 | 15 | ||
2003-08-05 | 2003-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2022-10-26 | 2022-09-30 | -0.01 | -0.04 | -0.03 | 300 |
Biomarin Pharmaceutical Target Price Consensus
Biomarin target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Biomarin Pharmaceutical's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 26 | Strong Buy |
Most Biomarin analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Biomarin stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Biomarin Pharmaceutical, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBiomarin Pharmaceutical Target Price Projection
Biomarin Pharmaceutical's current and average target prices are 70.69 and 97.66, respectively. The current price of Biomarin Pharmaceutical is the price at which Biomarin Pharmaceutical is currently trading. On the other hand, Biomarin Pharmaceutical's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Biomarin Pharmaceutical Market Quote on 26th of March 2025
Target Price
Analyst Consensus On Biomarin Pharmaceutical Target Price
Biomarin Pharmaceutical Analyst Ratings
Biomarin Pharmaceutical's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Biomarin Pharmaceutical stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Biomarin Pharmaceutical's financials, market performance, and future outlook by experienced professionals. Biomarin Pharmaceutical's historical ratings below, therefore, can serve as a valuable tool for investors.Know Biomarin Pharmaceutical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomarin Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomarin Pharmaceutical backward and forwards among themselves. Biomarin Pharmaceutical's institutional investor refers to the entity that pools money to purchase Biomarin Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-12-31 | 2.4 M | Northern Trust Corp | 2024-12-31 | 1.7 M | Deutsche Bank Ag | 2024-12-31 | 1.7 M | Jpmorgan Chase & Co | 2024-12-31 | 1.5 M | Ubs Group Ag | 2024-12-31 | 1.5 M | Venbio Select Advisor Llc | 2024-12-31 | 1.5 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.3 M | Aqr Capital Management Llc | 2024-12-31 | 1.3 M | Blackrock Inc | 2024-12-31 | 23.5 M | Vanguard Group Inc | 2024-12-31 | 19.4 M |
Biomarin Pharmaceutical's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.73 B.Market Cap |
|
Biomarin Pharmaceutical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.08 | 0.08 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.08 | 0.08 |
Determining Biomarin Pharmaceutical's profitability involves analyzing its financial statements and using various financial metrics to determine if Biomarin Pharmaceutical is a good buy. For example, gross profit margin measures Biomarin Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biomarin Pharmaceutical's profitability and make more informed investment decisions.
Biomarin Pharmaceutical's Earnings Breakdown by Geography
Evaluate Biomarin Pharmaceutical's management efficiency
Biomarin Pharmaceutical has return on total asset (ROA) of 0.0515 % which means that it generated a profit of $0.0515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0805 %, meaning that it created $0.0805 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of March 2025, Return On Tangible Assets is likely to grow to 0.07. Also, Return On Capital Employed is likely to grow to 0.08. At this time, Biomarin Pharmaceutical's Net Tangible Assets are very stable compared to the past year. As of the 26th of March 2025, Return On Tangible Assets is likely to grow to 0.07, while Intangible Assets are likely to drop about 245.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 29.77 | 31.26 | |
| Tangible Book Value Per Share | 27.40 | 28.77 | |
| Enterprise Value Over EBITDA | 18.68 | 19.61 | |
| Price Book Value Ratio | 2.21 | 3.91 | |
| Enterprise Value Multiple | 18.68 | 19.61 | |
| Price Fair Value | 2.21 | 3.91 | |
| Enterprise Value | 15 B | 9.8 B |
The strategic initiatives led by Biomarin Pharmaceutical's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.329 |
Basic technical analysis of Biomarin Stock
As of the 26th of March, Biomarin Pharmaceutical shows the Mean Deviation of 1.15, downside deviation of 1.85, and Risk Adjusted Performance of 0.0603. Biomarin Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Biomarin Pharmaceutical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomarin Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomarin Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomarin Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biomarin Pharmaceutical's Outstanding Corporate Bonds
Biomarin Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomarin Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomarin bonds can be classified according to their maturity, which is the date when Biomarin Pharmaceutical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC 405 Corp BondUS09062XAF06 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Biomarin Pharmaceutical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Biomarin Pharmaceutical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0603 | |||
| Market Risk Adjusted Performance | 0.4598 | |||
| Mean Deviation | 1.15 | |||
| Semi Deviation | 1.63 | |||
| Downside Deviation | 1.85 | |||
| Coefficient Of Variation | 1522.51 | |||
| Standard Deviation | 1.65 | |||
| Variance | 2.72 | |||
| Information Ratio | 0.0579 | |||
| Jensen Alpha | 0.0977 | |||
| Total Risk Alpha | 0.0928 | |||
| Sortino Ratio | 0.0515 | |||
| Treynor Ratio | 0.4498 | |||
| Maximum Drawdown | 8.07 | |||
| Value At Risk | (3.32) | |||
| Potential Upside | 3.04 | |||
| Downside Variance | 3.43 | |||
| Semi Variance | 2.66 | |||
| Expected Short fall | (1.07) | |||
| Skewness | (0.20) | |||
| Kurtosis | 1.61 |
| Risk Adjusted Performance | 0.0603 | |||
| Market Risk Adjusted Performance | 0.4598 | |||
| Mean Deviation | 1.15 | |||
| Semi Deviation | 1.63 | |||
| Downside Deviation | 1.85 | |||
| Coefficient Of Variation | 1522.51 | |||
| Standard Deviation | 1.65 | |||
| Variance | 2.72 | |||
| Information Ratio | 0.0579 | |||
| Jensen Alpha | 0.0977 | |||
| Total Risk Alpha | 0.0928 | |||
| Sortino Ratio | 0.0515 | |||
| Treynor Ratio | 0.4498 | |||
| Maximum Drawdown | 8.07 | |||
| Value At Risk | (3.32) | |||
| Potential Upside | 3.04 | |||
| Downside Variance | 3.43 | |||
| Semi Variance | 2.66 | |||
| Expected Short fall | (1.07) | |||
| Skewness | (0.20) | |||
| Kurtosis | 1.61 |
Consider Biomarin Pharmaceutical's intraday indicators
Biomarin Pharmaceutical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biomarin Pharmaceutical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 70.69 | |||
| Day Typical Price | 70.69 | |||
| Price Action Indicator | (0.42) | |||
| Period Momentum Indicator | (0.84) | |||
| Relative Strength Index | 59.02 |
Biomarin Pharmaceutical Corporate Filings
F4 | 20th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 7th of March 2025 Other Reports | ViewVerify | |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 26th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Biomarin Stock media impact
Far too much social signal, news, headlines, and media speculation about Biomarin Pharmaceutical that are available to investors today. That information is available publicly through Biomarin media outlets and privately through word of mouth or via Biomarin internal channels. However, regardless of the origin, that massive amount of Biomarin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biomarin Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biomarin Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biomarin Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biomarin Pharmaceutical alpha.
Biomarin Pharmaceutical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Biomarin Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biomarin Pharmaceutical Historical Investor Sentiment
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biomarin Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biomarin Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biomarin Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Biomarin Pharmaceutical.
Biomarin Pharmaceutical Maximum Pain Price Across May 16th 2025 Option Contracts
Biomarin Pharmaceutical's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Biomarin Pharmaceutical close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Biomarin Pharmaceutical's options.
Biomarin Pharmaceutical Corporate Management
| Laura Woodhead | VP Counsel | Profile | |
| George Davis | Chief VP | Profile | |
| Traci McCarty | Group Relations | Profile | |
| Jonathan Day | Executive Science | Profile | |
| Cristin Hubbard | Executive Officer | Profile | |
| Marni Kottle | Executive Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Biomarin Pharmaceutical's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.